FDA Adverse Event Injury Summary report: N

XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 2131619 · Received June 16, 2011

Report

Report Number
2024168-2011-04260
Event Type
Injury
Date Received
June 16, 2011
Date of Event
January 1, 2011
Report Date
May 5, 2011
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P070015
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. THERE WAS NO REPORTED PRODUCT DEFICIENCY. THE REPORTED ANGINA AND RE-STENOSIS ARE LISTED IN THE INSTRUCTIONS FOR USE AS KNOWN ADVERSE EVENTS ASSOCIATED WITH CORONARY STENTING. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECTS, AND THE RELATIONSHIP TO THE PRODUCT, IF ANY, CANNOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURING, DESIGN OR LABELING AND THE TREATMENT APPEARS TO BE RELATED TO THE OPERATIONAL CONTEXT OF THE PROCEDURE. THE OTHER TWO XIENCE V STENTS ARE BEING REPORTED UNDER SEPARATE MEDWATCH REPORT NUMBERS.

Description of Event or Problem · 1

IT WAS REPORTED THAT APPROXIMATELY 4 YEARS POST IMPLANTATION OF THREE XIENCE V STENTS IN THE DISTAL TO MID RIGHT CORONARY ARTERY (D-MRCA), THE PATIENT EXPERIENCED CHEST PAIN AND SHORTNESS OF BREATH DUE TO IN-STENT RESTENOSIS OF THE MRCA AND DRCA. ON (B)(6) 2011, THE PATIENT WAS HOSPITALIZED FOR BALLOON ANGIOPLASTY AND PLACEMENT OF A NON-ABBOTT STENT TO THE RESTENOSED STENTS. ALSO, A NEW LESION IN THE POSTERIOR DESCENDING ARTERY WAS TREATED. THERE WAS NO ADVERSE PATIENT SEQUELA AND ON (B)(6) 2011, THE PATIENT WAS DISCHARGED. ALTHOUGH REQUESTED, THERE WAS NO ADDITIONAL INFORMATION PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 60601P1

Patients

Seq Age Sex Outcome Treatment
1 59 YR Hospitalization| R STENT: XIENCE V STENTS (X2)